Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42Lymphoma, Follicular 31Lymphoma, Mantle-Cell 22Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Large B-Cell, Diffuse 15Lymphoma 13Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell 8Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 4Neoplasm, Residual 3Leukemia 3Waldenstrom Macroglobulinemia 2Recurrence 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 2Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, B-Cell 1Indolent Non-Hodgkin's Lymphoma 1Indolent Non-Hodgkin Lymphoma 1Hodgkin Disease 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Anemia 1

Interventions

Peripheral Blood Stem Cell Transplantation 36fludarabine phosphate 33Cyclophosphamide 31Mycophenolic Acid 26Whole-Body Irradiation 23Tacrolimus 22Cyclosporine 19Radiotherapy 16Busulfan 16Antilymphocyte Serum 15Methotrexate 14Filgrastim 12Etoposide 12Flow Cytometry 11Rituximab 8Methylprednisolone 8Melphalan 8Brentuximab Vedotin 8pembrolizumab 7Therapeutics 7Lenalidomide 7Bortezomib 7Psychiatric Rehabilitation 6Gemcitabine 6Cord Blood Stem Cell Transplantation 6Bexarotene 6romidepsin 5mogamulizumab 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mycosis Fungoides × obinutuzumab × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡